Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
February 19 2015 - 4:05PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company
focused on the discovery, development and commercialization of
recombinant nanoparticle vaccines and adjuvants, today announced it
will report its fourth quarter and full year 2014 financial and
operating results after the close of U.S. financial markets on
Thursday, February 26, 2015.
In addition, management will host a conference call to discuss
the quarterly and year-end financial results and provide an update
on corporate activities.
Conference call details are as
follows: |
Date: |
February 26, 2015 |
Time: |
4:30 pm US Eastern Time |
Dial-in number: |
(877) 212-6076 (Domestic) or (707) 287–9331
(International) |
Via web: |
www.novavax.com |
Conference call replay: |
Dates: |
Starting at 6:31 pm ET on February 26, 2015
until midnight March 5, 2015 |
Dial-in number: |
(855) 859-2056 (Domestic) or (404) 537-3406
(International) |
Passcode: |
89629680 |
Via web: |
www.novavax.com, "Investor
Info"/"Events" |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company
committed to delivering novel products to prevent a broad range of
infectious diseases. Our recombinant nanoparticles and Matrix-M™
adjuvant technology are the foundation for groundbreaking
innovation that improves global health through safe and effective
vaccines. Additional information about Novavax is available on the
company's website, novavax.com.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
240-268-2000
ir@novavax.com
Novavax, Inc.
David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
212-845-4271
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024